Bionexus Gene Lab Corp. — Q1 2019 Form 10-Q Summary
Business Context and Reporting Period
The filing covers the unaudited three months ended March 31, 2019. Bionexus Gene Lab Corp. is a Wyoming holding company whose wholly owned Malaysian subsidiary operates an emerging molecular diagnostics business focused on blood analysis, early disease detection, and personalized health management. The company operates a laboratory in Penang and a blood collection center in Kuala Lumpur.
The company is a smaller reporting company and an emerging growth company. It reported 74,627,558 common shares outstanding as of March 31, 2019 and May 6, 2019.
Financial Results and Key Metrics
| Metric | Three Months Ended March 31, 2019 | Three Months Ended March 31, 2018 |
|---|---|---|
| Revenue | $28,088 | $0 |
| Cost of revenue | $18,822 | $12,530 |
| Gross profit/(loss) | $9,266 | $(12,530) |
| Gross margin | Approximately 33.0% | Not meaningful |
| Other income | $7,020 | $266,979 |
| General and administrative expenses | $76,489 | $36,588 |
| Operating loss/(profit) | $(60,203) | $271,861 |
| Income tax expense | $1,264 | $0 |
| Net loss/(profit) | $(61,467) | $271,861 |
| Comprehensive loss/(profit) | $(44,502) | $273,614 |
| Basic and diluted loss per share | Reported as $0 | Reported as $0 |
Based on reported figures, the operating margin was approximately negative 214.3% and the net margin was approximately negative 218.8%. Revenue began in the prior year after the company commenced product sales in July 2018, according to management's discussion.
Cash Flow, Liquidity, Assets, and Debt
| Metric | March 31, 2019 | December 31, 2018 |
|---|---|---|
| Cash and bank balances | $597,463 | $659,235 |
| Fixed deposits | $615,491 | $601,004 |
| Total cash and cash equivalents | $1,212,954 | $1,260,239 |
| Total current assets | $1,249,788 | $1,298,354 |
| Total current liabilities | $66,182 | $62,893 |
| Working capital | $1,183,606 | $1,235,461 |
| Total assets | $1,607,160 | $1,652,239 |
| Total liabilities | $129,556 | $130,313 |
- Operating cash flow was $(48,561), compared with $(673,561) in the prior-year quarter.
- Investing cash flow was $(14,631), primarily reflecting $14,631 of plant and equipment purchases.
- Financing cash flow was $(3,606), reflecting repayment of a finance lease. The filing reports current and non-current finance lease obligations totaling $78,457 at March 31, 2019.
- Net cash decreased by $47,285 during the quarter, and ending cash and cash equivalents were $1,212,954.
- Management stated that cash flow from operations, together with existing resources, is expected to support the current level of operations for at least the next 12 months.
Material Changes Versus the Prior Comparable Period
- Revenue increased from zero to $28,088 as commercial product sales commenced after the prior-year quarter.
- Gross results improved from a $12,530 loss to a $9,266 profit, although the business remained loss-making after operating expenses.
- General and administrative expenses increased approximately 109% to $76,489, attributed to office renovations, furniture and fixtures, higher depreciation, professional fees, marketing, and travel expenses.
- Other income declined to $7,020 from $266,979. The prior-year amount primarily reflected a shareholder's waiver of amounts due for equipment and consumable stock transferred to the subsidiary.
- The company shifted from a $271,861 operating profit and net profit in the prior-year quarter to a $60,203 operating loss and $61,467 net loss.
- Operating cash use improved substantially from $673,561 to $48,561, but financing provided $1,116,681 in the prior-year period compared with a $3,606 use of cash in the current period.
- Accumulated losses increased from $86,842 at December 31, 2018 to $148,309 at March 31, 2019.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide specific revenue, earnings, or operating guidance. Management identified anticipated liquidity uses including additional administrative and marketing personnel, website development, advertising and marketing, and the costs of being a public company.
Key disclosed risks include limited operating history and business growth, uncertainty regarding the efficacy of the blood-screening process, potential product-liability claims without insurance coverage, and risks associated with operating in Malaysia, including enforcement of judgments against the subsidiary and management. Results may also be affected by foreign-currency translation; the quarter included a $17,145 foreign-currency translation gain.
Management reported no material pending legal proceedings, contractual obligations, off-balance-sheet arrangements, material subsequent events, or impairment charges. The filing states that disclosure controls and procedures were not effective as of March 31, 2019. Management identified material weaknesses in internal control over financial reporting related to inadequate segregation of duties due to reliance on a single officer and director and the lack of a functioning audit committee with a majority of independent members. Remediation may not occur in the near term because of limited financial resources.
Important Facts for Investors to Verify
- Whether revenue growth can continue and whether the company can generate sufficient gross profit to cover substantially higher operating expenses.
- The commercial adoption, validation, regulatory status, and efficacy of the company's blood-screening technology.
- The sustainability of liquidity given recurring operating losses, expected marketing and public-company costs, and limited operating history.
- The nature and repayment terms of the finance lease obligations and the company's ability to fund future capital expenditures.
- Progress in remediating the disclosed material weaknesses in disclosure controls and internal control over financial reporting.
- The absence of insurance coverage for potential product-liability claims and the legal and enforcement risks associated with the Malaysian subsidiary.
- The prior-year $266,979 other-income item and the extent to which reported earnings comparisons are distorted by this nonrecurring shareholder waiver.